H.C. Wainwright analyst Edward White lowered his price target for TG Therapeutics to $21 after the company announced that the independent Data Safety Monitoring Board for the ongoing Phase 3 UNITY-CLL trial in chronic lymphocytic leukemia patients advised the company that interim overall response rate analysis could not be conducted at this time due to the data not being sufficiently mature to conduct the analysis. The analyst pushed back the timing of his expectations of the launch for chronic lymphocytic leukemia to early 2021 from late 2019 and lowered the probability of success to 45% in the CLL indication from 55%. He keeps a Buy rating on TG Therapeutics.

Bullish option flow detected in TG Therapeutics with 1,058 calls trading, 1.2x expected, and implied vol increasing over 2 points to 100.79%. Jun-24 12 puts and Jun-24 17 calls are the most active options, with total volume in those strikes near 600 contracts. The Put/Call Ratio is 0.46. Earnings are expected on April 29th.